Payment overview · 2025
General Payments
$2,805.67
117 reported records · 25 companies
Healthcare provider profile · identity verified
Narendra Malani, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN RAMON, CA · NPI 1699732727
Verified facts
What the public records show
CMS Open Payments records show Narendra Malani, MD received $2,805.67 in general payments during 2025 across 117 reported records.
GlaxoSmithKline, LLC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $566.45 | 20.2% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $557.60 | 19.9% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.82 | 6.5% | 17 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $160.41 | 5.7% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $156.15 | 5.6% | 11 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $146.52 | 5.2% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $140.38 | 5.0% | 5 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $137.53 | 4.9% | 5 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $104.50 | 3.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $78.99 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.51 | 2.0% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.15 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.59 | 1.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $51.08 | 1.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.00 | 1.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.55 | 1.4% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $40.35 | 1.4% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $37.46 | 1.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $34.04 | 1.2% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $34.01 | 1.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $32.20 | 1.1% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $31.15 | 1.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $22.21 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.64 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.38 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,636.69 | 115 |
| Education | $168.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $467.80 | 14 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $378.09 | 18 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $189.27 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $188.36 | 12 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $160.41 | 6 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $160.41 | 6 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $160.41 | 6 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $160.41 | 6 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $156.15 | 11 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $146.52 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $146.32 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $145.20 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $140.38 | 5 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $137.53 | 5 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $137.53 | 5 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $104.50 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $104.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.55 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $64.69 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.51 | 2 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $51.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $40.35 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $37.46 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $34.04 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 245 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 301 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
301 | 71 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
245 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 120 |
| Furosemide | Furosemide | 370 | 76 |
| Eliquis | Apixaban | 326 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 85 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 301 | 71 |
| Mirtazapine | Mirtazapine | 248 | 49 |
| Jardiance | Empagliflozin | 245 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 65 |
| Gabapentin | Gabapentin | 200 | 51 |
| Potassium Chloride | Potassium Chloride | 192 | 49 |
| Lisinopril | Lisinopril | 173 | 46 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 158 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 36 |
| Donepezil Hcl | Donepezil Hcl | 153 | 36 |
| Famotidine | Famotidine | 153 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 44 |
| Losartan Potassium | Losartan Potassium | 152 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 41 |
| Prednisone | Prednisone | 137 | 45 |
| Trazodone Hcl | Trazodone Hcl | 131 | 31 |
| Xarelto | Rivaroxaban | 127 | 13 |
| Montelukast Sodium | Montelukast Sodium | 114 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 58 |
| Simvastatin | Simvastatin | 110 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 31 |
| Allopurinol | Allopurinol | 107 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 30 |
| Spiriva Respimat | Tiotropium Bromide | 99 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 94 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 14 |
| Carvedilol | Carvedilol | 91 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 19 |
| Omeprazole | Omeprazole | 90 | 22 |
| Memantine Hcl | Memantine Hcl | 88 | 15 |
| Metformin Hcl | Metformin Hcl | 88 | 31 |
| Finasteride | Finasteride | 86 | 18 |
| Buspirone Hcl | Buspirone Hcl | 80 | 11 |
| Sertraline Hcl | Sertraline Hcl | 78 | 18 |
| Lorazepam | Lorazepam | 75 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 24 |
| Tramadol Hcl | Tramadol Hcl | 73 | 24 |
| Azithromycin | Azithromycin | 72 | 55 |
| Levetiracetam | Levetiracetam | 69 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 18 |
| Divalproex Sodium | Divalproex Sodium | 64 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 16 |
| Methenamine Hippurate | Methenamine Hippurate | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 34 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 14 |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | 14 |
| Midodrine Hcl | Midodrine Hcl | 45 | 15 |
| Digoxin | Digoxin | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Gemtesa | Vibegron | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 17 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 20 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 20 |
| Xifaxan | Rifaximin | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 15 |
| Linzess | Linaclotide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | 11 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 17 | suppressed |
| Alvesco | Ciclesonide | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Lactulose | Lactulose | 16 | 11 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Misoprostol | Misoprostol | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | 11 |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,805.67 · 117 records | GlaxoSmithKline, LLC. | AIRSUPRA, Arikayce, BREZTRI, CAPLYTA, CHARTIS CATHETER, CT THROMBECTOMY SYSTEM KIT, CUVITRU, DUPIXENT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FASENRA, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Hillrom - Monarch Airway Clearance System, INSPIRE, JARDIANCE, JASCAYD, KRYSTEXXA, NUCALA, OFEV, OPSUMIT, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, REXULTI, Radicava, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, Vest Therapy Und, XYWAV, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error